Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis

January 31, 2017- Interviewed by Steven E. Greer, MD Jerry S. Wolinsky, M.D.,

Neurologist at UTHealth,

This entry was posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas. Bookmark the permalink.

Leave a Reply